Direct Biologics Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
49
- Latest Deal Type
-
Series B
- Investors
-
3
Direct Biologics General Information
Description
Developer of regenerative therapies designed for developing Extracellular Vesicle products derived from adult human mesenchymal stem/stromal cells. The company's technology contains bioactive molecules with clinical therapeutic potential that are processed under controlled, specified, and validated current conditions that are compliant with the quality standards and stimulate a wide array of regulatory proteins to modulate within the normal healing cascade, enabling patients to have access to healing through advanced repairment and reconstruction of their tissue.
Contact Information
Website
www.directbiologics.comCorporate Office
- 5301 Southwest Parkway
- Building 1, Suite 415
- Austin, TX 78735
- United States
Corporate Office
- 5301 Southwest Parkway
- Building 1, Suite 415
- Austin, TX 78735
- United States
Direct Biologics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC (Series B) | 01-Jun-2025 | Completed | Clinical Trials - Phase 3 | |||
| 3. Reverse Merger | 15-Feb-2023 | Cancelled | Clinical Trials - Phase 3 | |||
| 2. Debt - PPP | 28-Apr-2020 | $434K | $3.5M | Completed | Clinical Trials - Phase 3 | |
| 1. Early Stage VC (Series A1) | 01-Jun-2019 | $3.5M | $3.5M | Completed | Clinical Trials - Phase 3 |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Direct Biologics Patents
Direct Biologics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260166087-A1 | Compositions and methods for treating acute respiratory distress syndrome | Pending | 05-Nov-2024 | ||
| WO-2026090438-A1 | Compositions and methods for treating acute respiratory distress syndrome | Pending | 25-Oct-2024 | ||
| WO-2026072817-A1 | Treatment of idiopathic facial paralysis with extracellular vesicle composition | Pending | 25-Sep-2024 | ||
| US-12502407-B2 | Treatment of fistula with bone marrow mesenchymal stem cell derived extracellular vesicles | Active | 25-Apr-2024 | ||
| US-20250332200-A1 | Treatment of fistula with bone marrow mesenchymal stem cell derived extracellular vesicles | Active | 25-Apr-2024 | A61K35/28 |
Direct Biologics Signals
Direct Biologics Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| IB Investments | Venture Capital | Minority | ||
| Tranquillion | Impact Investing | Minority | ||
| Granite Oak Capital | Other | Minority |
Direct Biologics Acquisitions (1)
Direct Biologics’s most recent deal was a Merger/Acquisition with Paisley Laboratories. The deal was made on 16-Nov-2018.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Paisley Laboratories | 16-Nov-2018 | Merger/Acquisition | Drug Discovery |
Direct Biologics FAQs
-
When was Direct Biologics founded?
Direct Biologics was founded in 2017.
-
Where is Direct Biologics headquartered?
Direct Biologics is headquartered in Austin, TX.
-
What is the size of Direct Biologics?
Direct Biologics has 49 total employees.
-
What industry is Direct Biologics in?
Direct Biologics’s primary industry is Drug Delivery.
-
Is Direct Biologics a private or public company?
Direct Biologics is a Private company.
-
What is Direct Biologics’s current revenue?
The current revenue for Direct Biologics is .
-
How much funding has Direct Biologics raised over time?
Direct Biologics has raised $3.5M.
-
Who are Direct Biologics’s investors?
IB Investments, Tranquillion, and Granite Oak Capital have invested in Direct Biologics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process